Pfizer's talazoparib extends PFS in phase III trial in metastatic breast cancer

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.

July 12, 2024

Chemotherapy disrupts gut microbiome in patients with breast cancer

Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition.

July 12, 2024

Vol.50 No.28

In Brief

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.

June 28, 2024

Vol.50 No.26

Obituary

“Father of tamoxifen” V. Craig Jordan dies at 76

Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.

June 14, 2024

Vol.50 No.24

By MD Anderson Cancer Center staff

In the Archives

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

V. Craig Jordan, a pharmacologist who discovered selective estrogen receptor modulators, died on June 9. Jordan, a professor at The University of Texas MD Anderson Cancer Center who was credited with discovery of tamoxifen, was 76. An obituary appears in this issue. Jordan appeared on the Cancer History Project podcast in 2022 to discuss...

June 14, 2024

Vol.50 No.24

Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer

YOU MAY BE INTERESTED IN

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Chemotherapy disrupts gut microbiome in patients with breast cancer

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

“Father of tamoxifen” V. Craig Jordan dies at 76

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

Renew today!

Subscriber content

Login